• The Scope of Things: Measuring Equity in Cancer Care

    Clinical Research News | In the latest episode of The Scope of Things, Eugene Manley, Jr., founder and CEO of the STEMM & Cancer Health Equity Foundation, explains how underrepresented populations, including Black, Hispanic, Indigenous, rural, low-income, immigrant, underinsured, and uninsured communities, are less likely to receive guideline-aligned biomarker testing and less likely to be asked about clinical trial participation at all.

    Jun 9, 2026

  • Regulatory Outlook in Diagnostics Innovative and Uncertain

    Clinical Research News | The diagnostics industry is at the intersection of enormous clinical development and technological change, enabling first-ever detection milestones heavily driven by artificial intelligence and multi-biomarker tests. But it has increasingly been coming into conflict with a decades-old regulatory system that didn’t anticipate these technological changes and a political environment that favors U.S. competition and innovation but is also interested in cutting the budget.

    Jun 4, 2026

  • A ‘Credit-Score-Like’ Risk Assessment System for Investigative Drugs

    Clinical Research News | VeriSIM Life is building the “full-stack predictive infrastructure” to help pharma companies foresee the challenges ahead in translating a molecule from laboratory discovery to a successful human therapy. The help comes in the form of a dynamic, “credit-score-like” assessment of the risk with inherent explainability and trust.

    Jun 3, 2026

  • Phesi Highlights Disconnect Between Protocols and Outcomes, Warns of AI Repetition

    Clinical Research News | An analysis released by Phesi suggests that the systematic use of historical protocol templates without using patient data and context to guide protocol design leads to flaws being scaled, rather than solved, by AI.

    Jun 2, 2026